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Neurodegenerative diseases (NDDs) originate from a loss of neurons in the central
nervous system and are severely debilitating. The incidence of NDDs increases with
age, and they are expected to become more common due to extended life expectancy.
Because no cure is available, these diseases have become a major challenge in
neurobiology. The increasing relevance of microRNAs (miRNAs) in biology has prompted
investigation into their possible involvement in neurodegeneration in order to identify new
therapeutic targets. The idea of using miRNAs as therapeutic targets is not far from
realization, but important issues need to be addressed before moving into the clinics.
Here, we review what is known about the involvement of miRNAs in the pathogenesis
of NDDs. We also report the miRNA expression levels in peripheral tissues of patients
affected by NDDs in order to evaluate their application as biomarkers of disease. Finally,
discrepancies, innovations, and the effectiveness of collected data will be elucidated and
discussed.
Keywords: microRNA, neurodegenerative diseases, biomarker, Parkinson’s disease, Alzheimer’s disease,
amyotrophic lateral sclerosis, Huntington’s disease
INTRODUCTION
Neurodegenerative diseases (NDDs) are a family of disorders
characterized by progressive loss of neuronal function and
structure, resulting in neuronal death in the nervous system.
Different types of NDDs exist, depending on the neuron popu-
lation affected; the most common are Alzheimer’s disease (AD),
Parkinson’s disease (PD), Huntington’s disease (HD), and amy-
otrophic lateral sclerosis (ALS). A commonality of NDDs is
that they are not monogenic or polygenic diseases, and they
are even more complicated because several events take part in
the pathogenesis independent of genetic mutations. The molec-
ular events responsible for neurodegeneration include oxidative
stress, axonal transport deficits, protein oligomerization and
aggregation, calcium deregulation, mitochondrial dysfunction,
neuron–glial interactions, neuroinflammation, DNA damage,
and aberrant RNA processing. The greatest risk factor for neu-
rodegeneration is advancing age in combination with mitochon-
drial DNA mutation and oxidative stress damage. Other possible
causes include gender, poor education, endocrine conditions,
oxidative stress, inflammation, stroke, hypertension, diabetes,
smoking, head trauma, depression, infection, tumors, vitamin
deficiencies, immune and metabolic conditions, and chemical
exposure. Because the pathogenesis of many of these diseases
remains unknown, the role of environmental factors needs to be
considered.
In the last few decades, NDDs have become a major challenge
in neurobiology due to their enormous and growing social and
economic implications in society. For the same reason, increasing
research efforts have investigated the underlying molecular mech-
anisms in order to find a cure. Based on the latest evidence
reviewed here, miRNA deregulation is emerging as a contribu-
tor to neurodegeneration by influencing most of the mechanisms
responsible for NDDs. Neurodegeneration can also be considered
to be an RNA disorder (Johnson et al., 2012) in which microR-
NAs play a major role. Studying miRNA involvement in NDDs
might also provide targets for innovative therapies. Until now,
patients affected by NDDs have been surgically and pharmaco-
logically treated without obtaining a resolute therapy, which is
due primarily to the fact that therapeutic approaches for NDDs
require the modulation of multiple targets and molecular path-
ways because they are multigenic diseases. Based on the evidence
that a single miRNA can influence several target genes, a whole
disease phenotype could potentially be modified by modulating
a single miRNA molecule, which makes these RNA molecules
very intriguing from a therapeutic point of view. Furthermore,
the identification of deregulated miRNAs in patients affected by
NDDs or any other disease might allow earlier diagnosis and
the monitoring of disease progress. The main challenge of using
proteins as targets for routine diagnostics is low sensitivity, repro-
ducibility, and specificity (Johnson et al., 2012). In conclusion,
the aim of this review is to elucidate the broad implications of
miRNAs in NDDs, but also to point out the need to overcome
technical difficulties related to the study of miRNAs in NDDs.
Finally, we also report in detail what has been discovered thus far
regarding the involvement of miRNAs in different NDDs in order
to evaluate their potential as therapeutic targets.
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NON-CODING RNAs
The sequencing of the human genome has demonstrated that
the transcriptional output of the human genome is extremely
rich in non-coding RNAs (ncRNAs) (Lipovich et al., 2010). Since
this discovery, expectations regarding ncRNAs have increased
exponentially. More importantly, the expectations have been sup-
ported by the development of next-generation sequencing tech-
nologies, which have revealed thousands of unknown ncRNAs.
The vocabulary for ncRNAs is still far from saturated. The fascina-
tion of functional non-protein coding RNAs is that they represent
a means for an organism’s cells (cells that are genetically iden-
tical) to develop unique identities and functions. RNA is part
of a mechanism that exerts control over DNA to guarantee the
expression of a specific repertoire of genes at the appropriate
level and with the appropriate timing. Two important classes of
functional RNAs can be distinguished: long non-coding RNAs
(lncRNAs) and small RNAs. LncRNAs account for the major-
ity of transcription, they have no unifying structure or function,
and they are solely defined as RNA transcripts greater than 200
nucleotides in length with no coding potential (Ponting et al.,
2009). Relatively few lncRNAs have been characterized function-
ally, but increasing evidence suggests important roles for the
thousands of uncharacterized transcripts. LncRNAs have been
shown to target proteins to specific genomic loci, affecting tran-
scription patterns (Plath et al., 2003; Silva et al., 2003; Kohlmaier
et al., 2004; Zhao et al., 2008); to modulate the activity of protein-
binding partners (Dreyfuss et al., 2002; Allen et al., 2004; Espinoza
et al., 2004; Feng et al., 2006; Shamovsky et al., 2006; Mariner
et al., 2008); to function as precursors for small RNAs (Kapranov
et al., 2007; Fejes-Toth et al., 2009) to affect the processing of other
RNAs (Hellwig and Bass, 2008); and to modulate translation,
DNA methylation, and chromatin.
In contrast to lncRNAs, the biogenesis and function of small
RNAs is well known and can be divided into five classes: (i)
short interfering (si) RNAs (Elbashir et al., 2001a), (ii) small
temporal (st) RNAs (Pasquinelli et al., 2000), (iii) heterochro-
matic siRNAs (Reinhart and Bartel, 2002), (iv) tiny non-coding
RNAs (Ambros et al., 2003), and (v) micro (mi) RNAs (Lagos-
Quintana et al., 2001; Lau et al., 2001; Lee et al., 2001).These
small RNAs are processed from longer precursors and loaded
into an Argonaute (Ago) family member within a large effec-
tor protein complex. The typical function of small RNAs is to
mediate the post-transcriptional gene silencing (PTGS) of tar-
get RNA transcripts. The best understood class of small RNAs is
miRNAs, which were first discovered by Lee et al. (1993). miR-
NAs are 21–22nt single-stranded RNAmolecules that inhibit gene
expression by binding to a complementary sequence in the 3’UTR
of target genes (Bartel, 2004). These molecules originate from
longer transcripts (pri-miRNA) that are processed by Drosha
nuclease to yield a short hairpin “pre-miRNA,” which is then pro-
cessed by Dicer to generate a double-stranded RNA of 21–22nt.
Only one of the two strands is loaded into the RNA-induced
silencing complex (RISC) that identifies target mRNA based on
sequence complementarity with the miRNA. One of the core
components of RISC is member of the Argonaute (Ago) pro-
tein family, in particular Ago1 and Ago2. After association with
RISC, the choice of post-transcriptional repression is determined
by sequence complementarity of the miRNA with its binding
sequence on the 3′UTR of target mRNA: mRNA cleavage will
happen when there is sufficient complementarity, otherwise inhi-
bition of protein translation will occur. (Hammond et al., 2000;
Elbashir et al., 2001a,b; Nykanen et al., 2001;Martinez et al., 2002;
Schwarz et al., 2002). The relevance of miRNAs has increased with
time; they are currently known to be involved in almost all bio-
logical processes and developmental programs (Bartel and Bartel,
2003; Carrington and Ambros, 2003; Hunter and Poethig, 2003).
The first evidence that ncRNAs play a key role in neurodevelop-
ment is the widespread transcription of ncRNAs in the developing
mammalian brain (Lagos-Quintana et al., 2002; Krichevsky et al.,
2003; Sempere et al., 2004; Smirnova et al., 2005; Bak et al., 2008).
Next generation sequencing allowed the identification of a group
of miRNAs that are enriched in the brain and whose expression
varies according to area of the brain (Landgraf et al., 2007). In
particular, neuronal-specific miRNAs have been demonstrated to
control neuronal differentiation, excitability, and function. These
brain-enriched miRNAs play a role in a wide range of neurode-
generative pathologies as disease-causing genes, biomarkers, or
actors in pathogenesis. The idea of using miRNAs as therapeu-
tic targets is not far from being realized. Two miRNA-based
therapeutic approaches can be applied: miRNA mimics and anti-
miRNAs. miRNAmimics are small RNAmolecules with the same
sequence as the mature miRNA of interest that are used to down-
regulate the expression of target proteins mimicking the miRNA
of interest. The desired effect is over-expression of miRNAs and
down-regulation of their target mRNA, which can be used as a
protective therapeutic strategy. This strategy has some important
challenges that need to be overcome before moving into the clinic.
First, the possibility exists that many out off object proteins might
also be down-regulated because they are targets of the miRNA
of interest. Second, the half-lives of mimics in vivo are not well
known. Third, treating the brain with miRNA mimics is difficult
because they need to pass through the blood-brain barrier (BBB).
The second approach is to deliver RNAmolecules with a sequence
complementary to themiRNA of interest. Stoffel’s group designed
“antagomirs,” RNA snippets conjugated to cholesterol molecules
that help the RNA enter a cell (Krutzfeldt et al., 2005). The limit
of antagomirs as a possible tool for treating NDDs is that they are
not able to cross the BBB and require a local injection. Another
strategy to inhibit endogenous miRNAs is to deliver synthetic
sponge mRNA, which contains several complementary binding
sites for the miRNA of interest (Kluiver et al., 2012a,b). Certain
long ncRNAs are able to base-pair with small RNAs, inhibit-
ing the ability of miRNAs to bind to their targets. Therefore,
lncRNAs are analogous to how artificial miRNA sponges func-
tion (Ebert et al., 2007). This hypothesis was demonstrated by
Franco-Zorrilla et al. (2007) with the long ncRNA induced by
phosphate starvation 1 (IPS1) in Arabidopsis thaliana (Catarecha
et al., 2007). Future prospects regarding the administration of
miRNAs as therapeutics for NDDs will be discussed later.
NEURODEGENERATIVE DISEASES AND miRNAs
miRNAs IN PARKINSON’S DISEASE (PD)
PD is the second most common NDD, estimated to occur in
approximately 1% of individuals >60 years of age, with 4.1–4.6
million people affected worldwide. PD is a progressive neu-
rodegenerative disorder characterized clinically by bradykinesia,
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tremor, rigidity, and eventually postural instability (Shtilbans and
Henchcliffe, 2012). These symptoms are attributed to a loss of
dopaminergic neurons of the substantia nigra. The pathology
spreads to involve other brain regions, including the amygdala,
cingulate gyrus, and higher cortical regions, resulting in the devel-
opment of dementia and psychosis. The disease itself is quite het-
erogeneous, and symptom progression is variable (Mouradian,
2012).
Despite rigorous research efforts, patient management and
clinical research are still hampered by suboptimal methods for
diagnosis, refining the prognosis, predicting individual responses
to therapeutic interventions, and tracking disease progression.
The critical reliance of dopaminergic neurons on a functioning
miRNA network has been demonstrated in both cultured cells
and in vivo (Kim et al., 2007). The miRNA machinery is impor-
tant in NDDs in general and in PD in particular because the
recognition of the amount of certain pathogenic proteins in spe-
cific neuronal populations is critical for the survival of neurons
involved in the pathogenesis of disease. No cure is currently avail-
able for PD, and ongoing therapies are only directed at treating
the most bothersome symptoms. Treatment approaches include
medication (dopaminergic administration) and surgical therapy.
Other strategies include general lifestyle modifications (rest and
exercise), physical therapy, support groups, occupational therapy,
and speech therapy. Nevertheless, new experimental therapies are
under investigation and ongoing clinical trials are testing the
efficacy of anti-inflammatory (pioglitazone) and parasympath-
omimetic (rivastigmine) drugs, ganglioside administration, and
stemcell-based therapies. Even though PD is a multigenic disease,
one of the most promising therapeutic approaches is to com-
pensate biologically for the genetic defects responsible for PD
pathogenesis. Some efforts have been made in this direction in
the field of miRNAs, and the results are encouraging, even if far
from clinical implementation.
miR-7/miR-153 regulation of α-synuclein
A negative correlation has been reported with specific miRNAs
for two of the genes involved in PD: α-synuclein (SNCA) and
leucine-rich repeat kinase2 (LRRK2). SNCA localizes in presy-
naptic terminals, where it associates with the plasma membrane.
The protein is widely expressed in the adult brain, particularly
the neocortex, hippocampus, and substantia nigra (Jakes et al.,
1994;Mori et al., 2002;Wislet-Gendebien et al., 2008). The 3′UTR
of the human protein is more than twice as long as the coding
sequence and highly conserved (Sotiriou et al., 2009). This reports
simply a relevant role for the 3′in stabilizing SNCA mRNAs and
regulating its translation into protein. Point mutations and gene
duplication and triplication events in the SNCA locus have been
identified in a number of families with autosomal dominant early
onset PD (Singleton et al., 2003; Wood-Kaczmar et al., 2006).
Higher expression of wild-type SNCA and expression of the three
mutant forms of SNCA give rise to insoluble aggregates that con-
stitute the main structure of the Lewy Bodies (Masliah et al.,
2000; Tan and Skipper, 2007; Saiki et al., 2011). Thus, down-
regulation of SNCA represents a possiblemechanism for resolving
PD. Two miRNAs have been demonstrated to inhibit the expres-
sion of SNCA: miR-7 and miR-153 (Junn et al., 2009; Doxakis,
2010) (Table 1). Both miRNAs are highly enriched in the brain
(Bak et al., 2008), and their sequences are conserved among
different organisms. miR-153, in particular, is conserved across
vertebrate species. Both miRNAs inhibit SNCA mRNA and pro-
tein (Junn et al., 2009; Doxakis, 2010), with an additive effect
(Doxakis, 2010). Interestingly, the expression profile of these two
miRNAs in the brain of post-natal day 1 mice is similar to α-
synuclein protein and mRNA, and has been localized primarily
to the neurons of the midbrain, hippocampus, and cortex (Junn
et al., 2009; Doxakis, 2010). Co-localization of a miRNA with
its target gene suggests tight control of the amount of the target
gene produced.
miR-205/let-7/miR-184 ∗ regulation of LRRK2
LRRK2 is a member of the leucine-rich repeat kinase family
and is present largely in the cytoplasm, but also associates with
Table 1 | Specific target genes of miRNAs involved in
neurodegeneration are listed.
NDDs miRNAs Target genes References
PD miR-7 DP Junn et al., 2009;
Doxakis, 2010
miR-153 E2F1 Doxakis, 2010
let-7 LRRK2 Junn et al., 2009;
Gehrke et al., 2010
miR-184* LRRK2 Gehrke et al., 2010
miR-433 FGF20 Davis et al., 2005;
Wang et al., 2008a,b
miR-205 LRRK2 Cho et al., 2013
AD miR-106a, -520c APP Patel et al., 2008
miR-20a, -106a/b, -17 APP Hebert and De
Strooper, 2009
miR-16, -101 APP Long and Lahiri, 2011
miR-147, -655,
-323-3p, -644, -153
APP Delay et al., 2011
miR-124 APP splicing Smith et al., 2011
miR-29a, -29b-1, -9 BACE1 Hebert and De
Strooper, 2009
miR-298, -328, -195 BACE1 Boissonneault et al.,
2009; Zhang, 2012
miR-124 BACE1 Fang et al., 2012
miR-98 IGF1 Hu et al., 2013
miR-181c, -137 SPTLC1 Geekiyanage and
Chan, 2011
miR-29a, -29b-1, -9 SPTLC2 Geekiyanage and
Chan, 2011
miR-34a TAU Dickson et al., 2013
ALS miR-206 HDAC4 Williams et al., 2009
miR-9 NEFH Haramati et al., 2010
HD miR-9 REST Juliano et al., 2008
miR-9* CoREST Juliano et al., 2008
miR-196a mut-Htt Cheng et al., 2013
NDDs, neurodegenerative diseases; PD, Parkinson’s Disease; AD, Alzheimer
Disease; ALS, Amiotrophic Lateral Sclerosis; HD, Huntington’s disease.
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the mitochondrial outer membrane. It is highly expressed in the
brain, with the highest levels of expression in the hippocampus
and striatum (Galter et al., 2006; Melrose et al., 2006). LRRK2
is involved in the early development of neuronal processes
(Parisiadou et al., 2009) and gain-of-function mutations cause
familial as well as sporadic PD (Zimprich et al., 2004). Recent
investigations in flies have demonstrated that the mutated form
of LRRK2 (mut-LRRK2) is responsible for a reduced miRNA-
mediated gene repression. This is due to the fact that mut-LRKK2
physically interacts with Ago1 and Ago2—two components of
the RISC—inducing their down-regulation in aged Drosophila
Melanogaster (Gehrke et al., 2010). Gehrke et al. also investigated
the possible target mRNAs whose translation is induced by mut-
LRRK2 and identified E2F1 and DP. Flies expressing mut-LRRK2
were in fact characterized by higher expression levels of E2F1 and
DP, and down-regulation of E2F1 and DP suppressed the death of
dopaminergic neurons. Finally Gehrke S et al. demonstrated that
miR-184∗ and let-7, respectively, repressed E2F1 andDP (Table 1)
and that inhibition of thesemiRNAs in wild-type animals was suf-
ficient to phenocopy pathogenic LRRK2. In line with this, both
let-7 andmiR-184∗ have been demonstrated to regulate dopamin-
ergic survival and activity (Junn et al., 2009; Gehrke et al., 2010).
Regardless the role of mut-LRRK2 in PD, latest studies investi-
gated the consequences of wild-type LRRK2 deregulation in PD
pathogenesis. In particular LRRK2 gene locus was identified as
a genetic risk factor for the more common sporadic PD (Satake
et al., 2009; Simon-Sanchez et al., 2009), indicating that alter-
ation of its expression might be part of PD etiology. Moreover,
up-regulation of LRKK2 in an animal model of PD quickened
neurodegeneration (Lin et al., 2009). Basing on these evidences,
Cho et al. analyzed the expression levels of LRKK2 (protein and
mRNA) in the frontal cortex tissue of 8 sporadic PD patients and
relative control subjects. No differences in the mRNA levels were
found but affected brains were characterized by higher expression
levels of LRRK2 protein, suggesting a miRNA-mediated regula-
tion of this protein. In silico analysis has demonstrated a predicted
binding site for miR-205 in the 3′UTR of LRKK2 and in vitro
experiments confirmed a direct inhibition of LRKK2 via miR-
205. Finally they demonstrated that transfection of miR-205 in
the neurons expressing a PD-related LRKK2 R1441G mutant
prevented the neurite outgrowth defects (Cho et al., 2013).
miR-433 regulation of FGF20
Fibroblast growth factor 20 (FGF20) is a neurotrophic factor
preferentially expressed in the substantia nigra that sustains
the survival of dopaminergic neurons (Ohmachi et al., 2000,
2003). In contrast to this pro-survival activity, FGF20 treat-
ment of human neuroblastoma cell line SH-SY5Y increases the
amount of endogenous SNCA, demonstrating an anti-survival
role of FGF20 in dopaminergic neurons. Single nucleotide poly-
morphisms (SNPs) in the 3′UTR of this gene (i.e., rs1721100,
ss20399075, and rs12720208) have been found to be associated
with PD (Wang et al., 2008a). Importantly, the latest poly-
morphism is within the miR-433 binding site (Davis et al.,
2005),which is highly enriched in the brain. Wang et al. demon-
strated that SNP rs12720208 avoids inhibition by FGF20 through
miR-433 (Wang et al., 2008a). Finally, subsequent investigations
failed to confirm a relationship between the rs12720208 genotype,
FGF20, and SNCA. These discrepancies are often related to the
ethnic origins or genetic backgrounds of PD patients.
miRNAs in the peripheral tissues of PD patients
The use of biomarkers in PD is a moot point, and no reliable
biomarker exists for this NDD, with the exception of the mono-
genetic form of PD. With the increasing relevance of miRNAs in
NDDs, some efforts have been made to investigate the possibil-
ity of miRNAs as biomarkers. In particular, qRT-PCR analyses of
peripheral blood isolated from eight untreated PD patients (NT)
and eight control subjects (CTR) showed that the expression lev-
els of three miRNAs (miR-1, miR-22∗, and miR-29a) distinguish
NT from CTR (Margis et al., 2011) (Table 2). A second study was
based on qRT-PCR analyses of plasma obtained from 31 NT and
25 CTR (Cardo et al., 2013) and identified seven over-expressed
miRNAs (miR-181c, miR-331-5p, miR-193a-3p, miR-196b, miR-
454, miR-125a-3p, and miR-137) in NT (Table 2). Discrepancies
may be attributed to intrinsic differences between the sample
types (Table 2).
miRNAs IN ALZHEIMER’S DISEASE (AD)
AD is the most common form of dementia in people over 65
years of age. The disease is characterized by progressive neuronal
loss and inflammation affecting memory, language, behavior,
and cognition. The disease is characterized by amyloid-β (Aβ)
deposition, neurofibrillary tangle (NFT) formation, and exten-
sive neuronal degeneration in the brain. Aβ is derived from
the sequential cleavage of amyloid precursor protein (APP) by
beta-site APP-cleaving enzyme 1 (BACE1) and the γ-secretase
complex. The precise pathological mechanisms underlying AD
are currently unknown. Clinical and research evidence indicates
that aberrant regulation of miRNA-dependent gene expression is
closely associated with molecular events responsible for Aβ pro-
duction, NFT formation, and neurodegeneration (Hebert and De
Strooper, 2007, 2009; Hebert et al., 2008; Wang et al., 2008b).
The regulation of APP is complex but represents a great chal-
lenge in the treatment of AD patients. Current drug discovery
approaches in AD have focused on (i) preventing Aβ formation
or increasing “normal” APP processing through the inhibition
of γ- and β-secretase or the activation of α-secretase activity
(Palop and Mucke, 2010; Saido and Leissring, 2012; Schenk et al.,
2012); removing existing amyloid deposits via immunothera-
peutic approaches,e.g., antibodies or vaccines against amyloid
(Schenk et al., 2012). The miRNA field has moved in the same
direction, and miRNAs have been discovered to regulate APP
expression in three different ways: directly, indirectly, and by
regulating the alternative splicing of its mRNA.
Direct inhibition of APP via miRNAs
Direct regulation of APP is mediated by miRNA binding to a spe-
cific sequence in the 3’UTR. Several miRNAs that inhibit APP
expression in vitro have been identified, including miR-106a and
miR-520c; members of the miR-20a family (e.g., miR-20a, miR-
106a/b, miR-17) (Hebert and De Strooper, 2009); miR-16 and
miR-101 (Vilardo et al., 2010; Long and Lahiri, 2011); and miR-
147, miR-655, miR-323-3p, miR-644, and miR-153 (Delay et al.,
Frontiers in Cellular Neuroscience www.frontiersin.org December 2013 | Volume 7 | Article 265 | 4
Maciotta et al. microRNAs and neurodegenerative diseases
Table 2 | miRNAs deregulation in NDDs patients.
NDD miRNAs Source Changes Patients (P) References
and controls (C)
PD miR-133b SNC Down-regulation 3P, 5C Kim et al., 2007
miR-34b/c SNC Down-regulation 11P, 6C Minones-Moyano et al., 2011
miR-1, -22*, -29a Peripheral blood Down-regulation 8P, 8C Margis et al., 2011
miR-181c, -331-5p, -193a-p, -196b, -454,
-125a-3p, -137
Plasma Over-expression 31P,25 C Cardo et al., 2013
AD miR-34a, -181b PBMC Over-expression 16P, 16C Schipper et al., 2007
miR -26a, -27b, -30e-5p, -34a, -92, -125, -145,
-200c, -381, -422a, -423
Hippocampus,
cerebellum, medial
frontal gyrus
Over-expression 15P, 12C Cogswell et al., 2008
miR-9, -132, -146b, -212 Down-regulation
let-7f, miR-105, -125a, -135a, -138, -141, -151,
-186, -191, -197, -204, -205,- 216, -302b, -30a-5p,
-30a-3p, -30b, -30c, -30d, -32, -345, -362, -371,
-374, -375, -380-3p, -429, -448, -449, -494, -501,
-517, -517b, -518b, 518f, 520a*, 526a Cerebrospinal fluid
Over-expression 10P, 10C
miR-10a, -10b, -125, -126*, -127, 142-5p, -143,
-146b, -154, -15b, -181a, -181c, -194, -195,
-199a*, -214, -221, -328, -422b, -451, -455, -497,
-99a
Down-regulation
miR-9, -125b, -146a, 155 Cerebrospinal fluid and
brain tissue derived
extracellular fluid
Over-expression 3P, 3C Lukiw, 2007
miR-26b Substanzia nigra Over-expression 10P, 8C Absalon et al., 2013
ALS miR-338-3p
Whole blood
Over-expression 12P, 8C De Felice et al., 2012
miR-451, -1275, -328, -638, -149, -665, -583 Down-regulation
miR-27a, -155, -146a, -32-3p CD14+CD16−
monocytes
Over-expression 8P, 8C Butovsky et al., 2012
miR-146*, -524-5p, 582-3p Spinal cord Over-expression 5P, 3C Campos-Melo et al., 2013
miR-24-2*, -142-3p, -142-5p, -1461, -146b, -155 Spinal cord Over-expression 16P, 12C Koval et al., 2013
HD miR-29a, -330
Brodmann’s area 4
Over-expression Johnson et al., 2008
miR-132 Down-regulation
miR-132, -196, -486
Brodmann’s area 4
Over-expression 19P, 7C Packer et al., 2008
miR-9, -9*, -124, - 29b, 17-3p, -22, -485-5p, 500,
-222
Down-regulation 19P, 7C
miR-100, -151-3p,-16, -219-2-3p, -27b, -451, -92a Frontal cortex and
striatum
Over-expression 11P, 11C Marti et al., 2010
miR-128, -139-3p,-222,-382,-433,-483-3p Frontal cortex and
striatum
Down-regulation 11P, 11C Marti et al., 2010
miR-34b Plasma Over-regulation 27P, 12C Gaughwin et al., 2011
NDDs, neurodegenerative diseases; PD, Parkinson’s Disease; AD, Alzheimer Disease; ALS, Amiotrophic Lateral Sclerosis; HD, Huntington’s disease.
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2011) (Table 1). Only a few of these miRNAs are deregulated in
the brains of AD patients (Hebert et al., 2008; Nunez-Iglesias
et al., 2010), and it is difficult to determine which of these
miRNAs regulate APP in vivo.
Indirect inhibition of APP via miRNAs
Indirect inhibition of APP via miRNAs is through the direct
down-regulation of genes in pathways regulating the expres-
sion, function, or processing of this protein. β-secretase BACE1,
insulin-like growth factor 1 (IGF-1), and serine palmitoyltrans-
ferase (SPT) influence APP expression and are modulated by
miRNAs.
BACE1 plays a pivotal role in regulating Aβ production by
cleaving APP and releasing APPβ. Hebert et al. demonstrated the
in vitro inhibition of BACE1 by miR-29a, miR-29b-1, and miR-
9 and confirmed an association between the down-regulation of
these miRNAs and AD (Hebert et al., 2008). Mice over-expressing
miR-29c are characterized by the down-regulation of BACE1
levels, demonstrating an in vivo effect on BACE1 modulation
(Zong et al., 2011). Other studies demonstrated a negative corre-
lation between BACE1 and miR-298/miR-328/miR-195 in several
animal models of AD and confirmed direct inhibition in dif-
ferent mouse cell lines (Boissonneault et al., 2009; Zhu et al.,
2012). Finally, the most conserved and abundantly expressed ner-
vous system-specific miR-124 has been shown to inhibit BACE1
expression in cultured rat PC12 cell lines and primary cultured
hippocampal neurons, a cellular model of AD (Fang et al., 2012).
De-regulation of IGF-1-mediated signaling has been corre-
lated with AD (Rosario, 2010). IGF-1 function in the brain
includes Aβ clearance from the brain and phosphorylation of tau
(Hong and Lee, 1997; Vargas et al., 2011). Hu et al. showed that
the expression of miR-98 negatively correlates with the IGF-1
expression level in a mouse model of AD. Furthermore, over-
expression of miR-98 in cellular models of AD is responsible for
the down-regulation of IGF-1, enhanced Aβ production, and tau
phosphorylation (Hu et al., 2013).
SPT, a heterodimer composed of serine palmitoyltransferase
long chain 1 (SPTLC1) and serine palmitoyltransferase long
chain 2 (SPTLC2), is the first rate-limiting enzyme in the de
novo ceramide synthesis pathway (Hannun and Obeid, 2008).
Membrane ceramides are known to contribute to AD pathol-
ogy by facilitating the mislocation of BACE1 and γ-secretase to
lipid rafts, thereby promoting Aβ formation (Lee et al., 1998;
Vetrivel et al., 2005). Interestingly, SPT is increased in the brain
of sporadic AD patients (Geekiyanage and Chan, 2011) with
up-regulation of several miRNAs, including miR-137, miR-181c,
miR-9, miR-29a, miR-29b-1, and miR-15. In vitro luciferase assay
confirmed direct inhibition of SPTLC1 bymiR-181c andmiR-137
and of SPTLC2 by miR-29a, miR-29b1, and miR-9. Moreover, a
negative correlation has been demonstrated between the expres-
sion levels of these miRNAs and their relative target genes,
SPTLC1 and SPTLC2, in the frontal cortices of sporadic AD
patients (Geekiyanage and Chan, 2011).
miRNAs regulating the alternative splicing of APP
Human APP exists as three major isoforms (APP751, APP770,
and APP695) originating from alternative splicing. Isoforms
APP751 and APP770 are widely expressed and contain the Kunitz
protease inhibitor (KPI) domain encoded by exon7, but only
APP770 contains the putative glycosylation domain OX2 encoded
by exon8. The APP695 isoform is majorly expressed in neu-
rons (Zhang et al., 2011) and contains neither the KPI nor OX2
domains. Changes in the expression profile of neuronal APP
are associated with an increase in Aβ production (Donev et al.,
2007). Higher expression of APP isoforms containing exons 7
and 8 is found in various areas of the brains of AD patients
(Golde et al., 1990; Neve et al., 1990; Jacobsen et al., 1991;
Tanzi et al., 1993; Rockenstein et al., 1995). To investigate the
involvement of miRNAs in the regulation of APP splicing, Smith
et al. created a forebrain-specific Dicer conditional knock-out
mouse in which post-mitotic neurons were characterized as hav-
ing increased levels of APP751 and APP770 isoforms. Because
miR-124 plays a pivotal role in neuronal maintenance and splic-
ing (Makeyev et al., 2007; Papagiannakopoulos and Kosik, 2009),
Smith et al. induced the ectopic expression ofmiR-124 inNeuro2a
cells, which was enough to induce the skipping of exons 7 and
8 by inhibiting polypyrimidine tract binding protein 1 (PTB1).
In addition, and supporting this observation, lower expression of
miR-124 was measured in the brains of AD patients (Smith et al.,
2011).
miR-34a/miR-26b regulation of tau protein
The microtubule-associated protein tau promotes the assembly
and stability of microtubules (Weingarten et al., 1975; Drubin
and Kirschner, 1986). It is involved in many NDDs, collectively
known as tauopathies (Lee et al., 2001). In the case of AD, tau is
hyperphosphorylatated and accumulates in the cytoplasm where
it gives origin to intraneuronal protein aggregates known as NFTs
(Kosik et al., 1986; Nukina and Ihara, 1986; Wood et al., 1986).
Although alterations in tau protein are not considered the earli-
est event in AD pathogenesis, reduction in its expression levels
may be safe and beneficial to prevent or treat AD (Rapoport et al.,
2002; Roberson et al., 2007; Ittner et al., 2010; Vossel et al., 2010).
In this optics, Dickson et al. investigated the role of the 3′UTR of
human tau mRNA in regulating tau expression. Using different
prediction algorithms, they found several miRNA-binding sites
and they were able to validate direct inhibition of human tau by
miR-34a (Dickson et al., 2013). Another approach to inhibit NFT
formation is represented by regulating the phosphorilation sta-
tus of tau protein. Tau is in fact a phosphoprotein that contains
more than 80 potential phosphorylation sites (Hanger and Noble,
2011). As mentioned above, hyperphosphorilation of tau causes
insoluble aggregates into the cytoplasm of neurons. In regard,
Absalon et al. identified a specific miRNA (miR-26b) that rises in
the substantia nigra at early stages of AD (Braak III) and remains
elevated in the pathological area of human AD brain during dis-
ease progression. A target mRNA of miR-26b was confirmed to
be Retinoblastoma (Rb). Both over-expression of miR-26b and
down-regulation of Rb in primary cortical neurons showed acti-
vation of cyclin-dependent kinase 5 (Cdk5) and enhanced tau
phosphorylation, followed by apoptosis and neurodegeneration
in vitro (Absalon et al., 2013). AntagomiR-26b based therapy
might not only decrease tau phosphorylation andNTF formation,
but also enhances neuronal survival.
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miR-146 regulation of presenilin
As described by Haas et al. the APP undergoes successive prote-
olysis by β- and γ-secretases to produce the Aβ that character-
istically deposits in AD brain (Hass et al., 2009). γ-Secretases is a
large complex of four integral membrane proteins, with presenilin
(PSEN) as the catalytic subunit. Dominant mutations in the genes
encoding for presenilins (PSEN1 and PSEN2) are the most com-
mon cause of familial early-onset Alzheimer’s disease (Brouwers
et al., 2008). These mutations alter the biochemical character of
the γ-secretase complex and its interaction with the APP sub-
strate, so that a longer and aggregation-prone form of Aβ is pro-
duced (Mucke and Selkoe, 2011). It is also to note that presenilins
function is likely to be relevant to the development of sporadic
AD. For all above reasons, presenilins together with β- and γ-
secretases are top targets for AD drug discovery. In addition to its
role in Aβ generation, PSEN2 was demonstrated to modulate the
microglia activity (Jayadev et al., 2013). More in detail, Jayadev
et al. demonstrated that in vivo deficiency of PSEN2 associated
with exaggerated pro-inflammatory state in microglia. Basing
on this evidence, they hypothesized that presenilin disfunctions
could contribute to AD neurotoxic inflammation (Jayadev et al.,
2010). In order to elucidate the underlining molecular mecha-
nisms, PSEN2 knockout (KO) and wt microglia were analyzed for
differential miRNA expression. The expression profiles of several
miRNAs involved in the regulation of innate immune signaling
were perturbed in PSENKO microglia, including miR-146 that is
a potent negative regulator of innate immunity. This observation
suggested that PS2 modulates cytokine responses via inhibition
of miR-146. In line with this evidence, the target mRNA of miR-
146a IRAK-1 (interleukin-1 receptor-associated kinase-1) was
increased in PS2KOmicroglia. One of the function of IRAK-1 is to
be a mediator of IL-1 (interleukin-1) signaling (Cao et al., 1996)
and a critical regulator of Toll-like receptor (TLR) signal trans-
duction (Swantek et al., 2000). When activated, IRAK-1 binds
to NFkB thereby promoting nuclear localization and transcrip-
tional activity (Flannery and Bowie, 2010). Indeed PS2KO vs. wt.
microglia showed increased NFkB activity upon stimulation with
lipopolysaccharide (LPS). Jayadev et al. strongly demonstrated
that PSEN2 influences microglia activity but the exact mechanism
by which PSEN2 carries out this task via miR-146modulation still
need to be elucidated (Jayadev et al., 2013).
miRNA profile of the brain and peripheral tissues in AD
In most cases, AD can only be diagnosed by neuropsychological
studies, neuroimaging, and clinical data from patients that allow
characterization as probable or possible AD patients (Mckhann
et al., 1984) with a sensitivity of 93% and specificity of 55%.
Furthermore, diagnosis is far more difficult in early and unusual
presentations of the disease. Several research efforts have exam-
ined miRNAs in order to identify potential biomarkers. In 2007,
the first small-scale profiling of miRNAs was performed on the
hippocampal region of fetal, adult, and AD brains (Lukiw, 2007).
Since then, several large-scale analyses have been performed on
different AD tissues, including brain, peripheral blood, and cere-
brospinal fluid (CSF) (Schipper et al., 2007; Cogswell et al.,
2008; Hebert et al., 2008; Wang et al., 2008a; Nunez-Iglesias
et al., 2010; Shioya et al., 2010). Nevertheless, miRNA expression
studies on AD patients have had either no or very little over-
lap in miRNA changes (Table 2). Schipper et al. analyzed blood
mononuclear cells (BMC) from patients with sporadic AD using
miRNA microarray analyses and found two miRNAs that are
significantly up-regulated in AD subjects: miR-34a and miR-
181b (Schipper et al., 2007) (Table 2). Cogswell et al. performed
qRT-PCR analysis on brain tissue and CSF from AD patients,
identifying a set of miRNAs, so-called AD-specific miRNAs, that
are differentially expressed in the brain and altered in the CSF
of AD patients (Cogswell et al., 2008) (Table 2). Finally, Lukiw
et al. group recently characterized the miRNome of AD CSF
and short post-mortem interval brain tissue-derived extracellu-
lar fluid (ECF) using fluorescent miRNA array, finding significant
increases inmiR-9, miR-125b, miR-146a, andmiR-155 in ADCSF
and ECF (Lukiw, 2007) (Table 2).
miRNAs IN AMYOTROPHIC LATERAL SCLEROSIS (ALS)
ALS is often referred to as “Lou Gehrig’s Disease.” It is a progres-
sive, idiopathic, fatal NDD that affects nerve cells in the brain and
spinal cord. Motor neuron loss gives rise to malfunctions in the
muscle tissue, causing weakness, atrophy, and ultimately paraly-
sis and death within 3 or 5 years of symptom onset. The disease
occurs worldwide with an incidence of approximately 2 × 105
and a prevalence of approximately 6–8 × 105. Currently, there is
only one FDA-approved compound; riluzole does not resolve the
disease, but slows progression and extends survival with modest
effects. The discovery of small molecules that change the course
of disease in ALS is desirable. With the increasing relevance of
miRNAs, many recent research efforts have investigated the role
of these small RNA molecules in the pathogenesis of ALS. The
data that have been obtained are encouraging but still in their
infancy, as they demonstrated an involvement but are far from
proposing a solution. Nevertheless, if we are able to improve our
understanding of the pathogenesis of ALS, it could lead to the
development of early and specific diagnostic methods and extend
the life expectancy of ALS patients. No definitive diagnostic tests
or biomarkers exist for ALS, and neurologists rely on clinical
criteria for diagnosis. The development of novel biomarkers to
evaluate disease progression could give us the ability to refine the
design of therapeutic trials and reduce the costs of clinical trials
(Kiernan et al., 2011).
miR-206 and re-innervation
One of themost promising studies toward an innovative approach
to cure ALS was conducted by Williams et al. (2009). miRNAs are
involved in the stress response in skeletal muscle (Van Rooij and
Olson, 2007). Because ALS is characterized by paralysis of the
lower limbs, Williams et al. investigated the miRNome of mus-
cles isolated from the lower limbs of an animal model of ALS,
SOD1 transgenic mice. MyomiR-206 (Chen et al., 2006; Rao et al.,
2006) was strongly induced, and its up-regulation coincided with
the onset of symptoms. After severing the sciatic nerve of wild-
type mice to induce denervation of the lower leg muscles, higher
expression levels of miR-206 were observed 10 days after surgery
in fast-twitch muscles, suggesting the involvement of this miRNA
in re-innervation. This hypothesis was confirmed when miR-
206 was knocked out in SOD1 transgenic mice, demonstrating
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accelerated progression of ALS and shortened survival (Williams
et al., 2009). The underlying molecular mechanism was investi-
gated and miR-206 was found to induce the secretion of fibrob-
last growth factor binding protein 1 (FGFBP1) from muscle by
inhibiting Histone deacetylase 4 (HDAC4) translation. FGFBP1
potentiates the effect of FGFs in the promotion of presynaptic
differentiation at the neuromuscular junction (Fox et al., 2007).
miRNA biogenesis and ALS
Multiple studies have identified several dominant mutations in
the 43-kDa trans-activating response region (TAR) DNA-binding
protein (TDP-43) in both sporadic and familial ALS patients that
are associated with other NDDs (Kabashi et al., 2008; Sreedharan
et al., 2008; Pesiridis et al., 2009; Lagier-Tourenne et al., 2010).
A functionally related gene, fused in sarcoma/translocation in
liposarcoma (FUS/TLS), is also mutated in ALS (Kwiatkowski
et al., 2009; Vance et al., 2009). These two DNA/RNA-binding
proteins physically interact with one another and are physiologi-
cally involved in the regulation of RNA transcription and splicing
(Giordana et al., 2010; Lagier-Tourenne et al., 2010). The exact
mechanism by which these proteins become pathogenic in ALS
remains uncertain, but the most assessed hypothesis is related
to their nuclear/cytoplasmic imbalance (Kwiatkowski et al., 2009;
Vance et al., 2009; Giordana et al., 2010). Moreover, Ling et al.
discovered that ALS-associated forms of TDP-43 have longer half-
lives, contributing to TDP-43 aggregation in ALS patients, and
they have an increased affinity for FUS/TLS (Ling et al., 2010).
By combining tandem-affinity purification and quantitative
mass-spectrometry analysis, Ling et al. discovered that TDP-
43 is associated with multiple hnRNP proteins and the Drosha
microprocessing complex (Ling et al., 2010). Similarly, data indi-
cated that Drosha protein is a putative FUS interactor (Gregory
et al., 2004). Association with Drosha and mislocation of TDP-
43 and FUS/TLS suggests de-regulation of miRNA biogenesis
in ALS. Independent from this study, knocking down TDP-43
in the human Hep-3B cell line was later shown to replicate
the changes occurring in the total miRNA population (Buratti
et al., 2010). A relationship was also demonstrated between
TDP-43 and brain-enriched miR-9; loss of Drosophila TDP-43
was characterized by down-regulation of miR-9a and TDP-43
influenced sensory organ precursor (SOP) cells in Drosophila
through miR-9a (Li et al., 2013). Regarding FUS/TLS, its down-
regulation in neuroblastoma cell line SK-N-BE affected the
biogenesis of a large class of miRNAs, including neuronal iso-
forms. FUS/TLS is recruited at the chromatin, where it directly
binds pri-miRNAs, facilitating Drosha loading (Morlando et al.,
2012).
miR-9 regulation of neurofilaments
Neurofilaments are components of the neuronal cytoskeleton and
provide structural support to the axons. They are assembled from
light, medium, and heavy subunits, creating three different types
of neurofilaments: light (NEFL), medium (NEFM), and heavy
(NEFH). If the expression of neurofilaments is not well orches-
trated, axonal cytoskeletal defects occur (Julien, 1999; Liem and
Messing, 2009). Perturbation of the fine neurofilaments is associ-
ated with the development of human ALS (Figlewicz et al., 1994;
Tomkins et al., 1998; Al-Chalabi et al., 1999). The 3′UTRs of
neurofilament-encoding genes appear to interact with an unchar-
acterized trans-acting factor that is attenuated in ALS (Haramati
et al., 2010), which might be miRNAs. In support of this hypoth-
esis, ablation of Dicer1 in post-mitotic post-natal motor neurons
fails to coordinate neurofilament subunit stoichiometry, but only
the expression levels of NEFH were perturbed. Prediction anal-
yses found one and nine binding sites for miR-9 in the 3′UTR
of NEFL and NEFH, respectively. Direct inhibition of NEFH
by miR-9 was confirmed by in vitro experiments (Table 1), but
no luciferase assays were performed to validate the NEFL/miR-9
interaction. Thus, dysregulation of neurofilament stoichiometry
in several motoneuron diseases is due to miR-9 loss (Haramati
et al., 2010). No further efforts have been made to understand the
involvement of miR-9 in ALS.
miRNA profile of the spinal cord in ALS
The first study aiming to characterize the miRNA profile in
the spinal cord of sporadic ALS patients was conducted by
Campos-Melo et al. (2013). They used a quantitative qRT-PCR-
based array method to screen 664 human miRNAs from the
spinal cords of three healthy controls and five ALS patients; they
identified 246 down-regulated and 10 up-regulated miRNAs
(Table 2). This was the only study reporting such a mass decrease
in the miRNA profile for NDDs. Interestingly, many of the
de-regulated miRNAs were predicted to have a binding site in
the 3′UTR of NEFL, and consistent inhibition was demonstrated
for miR-146∗, miR-524-5p, and miR-582-3p (Campos-Melo
et al., 2013). Around the same time, Koval et al. characterized the
expression of 613 miRNAs using miRNAmicroarray experiments
and the spinal cords of diseased rats and mice. Using individual
assays, 11 miRNAs were confirmed in the diseased mice, 10 in
SOD1G93A rats, and 6 in ALS patients (miR-24-2∗, miR-142-3p,
miR-142-5p, miR-1461, miR-146b, and miR-155) (Table 2).
More importantly, miR-155 was increased in both sporadic and
familial ALS patients, and when its expression was inhibited in
the brain of SOD1G93A rats in vivo, both survival and disease
duration were increased (Koval et al., 2013).
miRNAs in the peripheral tissues of ALS patients
De Felice et al. performed the first and only miRNA profiling of
leukocytes isolated from blood to identify characteristic patterns
in sporadic ALS patients (De Felice et al., 2012). Briefly, leuko-
cytes were isolated from the blood of 8 patients and 12 healthy
controls and screened for the expression of 911 human miR-
NAs using microarray technology. Eight miRNAs (miR-338-3p,
miR-451, miR-1275, miR-328, miR-638, miR-149, miR-665, and
miR-583) were de-regulated in ALS patients (Table 2). Among
these miRNAs, miR-338-3p was previously found in brain tissue
from ALS patients (Shioya et al., 2010).This study detected, for
the first time, specific disease-related changes in miRNAs at an
earlier stage of sporadic ALS.
Another study was performed on peripheral tissues from
ALS patients; in particular, the analyses were restricted to a
subgroup of monocytes (CD14+CD16−) isolated from ALS
patients. This population was chosen because its murine analog
(Ly6Chimonocytes) isolated from SOD1 mice has a pronounced
pro-inflammatory profile (gene and miRNA expression) prior
to disease onset and is recruited to the spinal cord, where
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the cells proliferate during disease progression. The human
CD14+CD16−monocytes isolated from ALS patients and Ly6Chi
monocytes isolated from SOD1 mice had a unique inflammatory
miRNA profile. Ly6Chi diseased monocytes were characterized by
the up-regulation of let- 7, miR-15b, miR-16, miR-27a, miR-34a,
miR-132, miR-146a, miR-155, miR-223, and miR-451 (Table 2).
HumanCD14+CD16−ALSmonocytes had higher expression lev-
els of miR-27a, miR-155, miR-146a, and miR-32-3p (Butovsky
et al., 2012) (Table 2). Finally, the authors underlined the poten-
tial role of these miRNAs as biomarkers of ALS.
miRNAs AND HUNTINGTON’S DISEASE (HD)
HD is an incurable neurodegenerative condition caused by CAG
repeat expansion in the huntingtin gene (Htt). HD patients man-
ifest cognitive defects and motor control impairment due to
neuronal dysfunction characterized by progressive loss of cortical
and striatal neurons. Neuronal death happens due to the toxicity
associated with the mutant Htt protein and loss of the neuro-
protective effects of the wild-type protein (Cattaneo et al., 2005).
Little is known about the function of Htt, but its mutant form
affects cellular phenotype and viability (Zuccato et al., 2010).
Several genes have been found to be altered in the brain of
HD patients (Cha, 2007), and many transcription factors (TFs)
interact with Htt and are recruited to the mutant Htt aggre-
gates (Sugars and Rubinsztein, 2003) in the brain. Recruitment
to Htt aggregates prevents TFs from binding to DNA and eliciting
their functions. More importantly, mutant Htt inhibits the for-
mation of processing bodies (P bodies) by interacting with Ago1
and Ago2, which are involved in miRNA biogenesis (Savas et al.,
2008). Thus, miRNA dysregulation is expected in the brain of HD
patients. Currently, no cure exists for HD; all of the treatments
are palliative. RNA therapy has emerged as a powerful tool for
modifying the disease course by targeting mutant HTT mRNA
for degradation.
miRNA profile in the brain of HD patients
Htt was demonstrated to interact with repressor element 1
silencing transcription factor (REST), the essential transcrip-
tional repressor also known as neuron-restrictive silencing factor
(NRSF), in neurons (Zuccato et al., 2003; Ooi and Wood, 2007).
In control individuals, Htt sequesters REST in the cytoplasm of
neurons and prevents the repressor from binding to DNA; in HD
patients the mutant Htt does not associate with REST, which relo-
cates to the nucleus of HD neurons and represses many of its
target genes. One of the target genes of REST is BDNF, which is
essential for neuron survival (Zuccato et al., 2003).
Based on the presence of REST binding sites in the genome,
Johnson et al. were able to identify a set of REST-target miRNAs
in the human genome (miR-9-1, 9-3, 29a, 29b-1, 124a-1, 124a-
2, 124a-3, 132, 135b, 139, 203, 204, 212, 330, and 346) that are
also brain or neuron-specific (Johnson et al., 2008). Among these
miRNAs, four (miR-29a, miR-124a, miR-132, and miR-330) were
found to be decreased in the cortex of R6/2mice, an animal model
of HD. Furthermore, their known target mRNAs were increased
in R6/2 mice (Johnson et al., 2008) Johnson et al. then analyzed
the expression profile of miR-29a, miR-124a, miR-132, and miR-
135b in parietal cortical tissues from control and HD individuals;
only down-regulation of miR-132 was confirmed in the human
samples (Table 2). Otherwise, the expression levels of miR-29a
andmiR-330 were increased andmiR-124a did not differ between
HD and control subjects (Johnson et al., 2008) (Table 2).
Packer et al. investigated whether miRNAs correlate with dis-
ease progression in HD patients by analyzing the expression
profile of predicted REST-regulated miRNAs in Brodmann’s area
4 (BA4) isolated from control and HD grade 1–4 brain samples
(Packer et al., 2008). Five miRNAs (miR-9, miR-9∗, miR-29b,
miR-124a, andmiR-132) were significantly different with increas-
ing HD grade (Packer et al., 2008). Otherwise, no correlation
with disease progression was observed for miR-139, miR-135b,
and miR-212. Next, a qRT-PCR-based miRNA array platform was
used to evaluate the expression profiles of 365 mature miRNAs in
the BA4 cortex from control and early stage HD (grades 1 and
2) patients. The de-regulation of additional miRNAs, including
miR-486, miR-196a, miR-17-3p, miR-22, miR-485-5p, miR-500,
and miR-222, was found (Packer et al., 2008).
Finally, Marti et al. analyzed the expression profile of miRNAs
in the frontal cortex and striatum of HD patients using three dif-
ferent techniques: RNA sequencing, microarray, and qRT-PCR.
miR-100, miR-151-3p, miR-16, miR-219-2-3p, miR-27b, miR-
451, and miR-92a were found to be over-expressed in diseased
tissues in all three experiments (Marti et al., 2010). Similarly, miR-
128, miR-139-3p, miR-222, miR-382, miR-433, and miR-483-3p
were decreased in the HD brain tissue in all three experiments
(Marti et al., 2010).
Based on the data above, 30miRNAs are increased and 24miR-
NAs are decreased in the brains of HD patients. De-regulation
of 33 of the 54 miRNAs associated with HD can be attributed
to four TFs that are altered in the HD brain; TP53, REST, E2F1,
and GATA4 (Sinha et al., 2012). In particular, TP53 is involved in
processing the primary miRNA transcript to the mature miRNA
(Suzuki et al., 2009). Because intronic miRNAs are transcribed
at the same levels as the host genes if oriented in the same
direction (Baskerville and Bartel, 2005; Wang et al., 2009), Sinha
et al. investigated a possible relationship between the host genes
and intronic miRNAs in HD. Thirty-one of the 54 miRNAs de-
regulated in the brains of HD patients are encoded within the
introns, and the expression of some of these miRNAs correlates
with the expression levels of their host genes (Sinha et al., 2012).
miR-9/9 ∗-REST/CoREST feedback in HD
As mentioned above, the expression levels of miR-9 and miR9∗
are decreased in the cerebral cortex of HD-affected subjects.
Interestingly these twomiRNAs target REST and CoREST, respec-
tively (Johnson and Bucley, 2009a). REST has been demonstrated
to inhibit the expression of neuronal genes in non-neuronal cells,
and under normal conditions it is retained in the cytoplasm by
interacting with Htt. When Htt is mutated, REST no longer asso-
ciates with Htt, which then relocates and accumulates in the
nucleus, where it inhibits the expression of several genes (Zuccato
et al., 2003). Decreased levels of miR-9/9∗ in HD would increase
the transcription of REST, amplifying the accumulation of this
protein in the presence of mutated Htt. This phenomenon is fur-
ther magnified because miR-9/9∗ transcription depends on REST.
Thus, the translocation of REST to the nucleus in HD brain
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tissues explains the reduced expression of miR-9/miR9∗ (Johnson
et al., 2009b).
miR-196a and HTT expression
Based on the results published by Packer et al. (2008) and on
unpublished microarray data from transgenic monkeys with HD,
Cheng et al. identified miR-196a as a possible miRNA involved
in the pathogenesis of HD. To further investigate the role of
this miRNA in HD, they co-transfected human embryonic kid-
ney and murine neuroblastoma cell lines with two constructs:
miR-196a mimic and the mutant form of Htt. These in vitro
experiments showed for the first time that miR-196a suppresses
the expression of mutant Htt at the mRNA and protein levels.
Furthermore, this inhibition was not due to the direct binding
of miR-196a to the3′UTR of mutated Htt. Otherwise, miR-196a
predominantly suppressed Htt expression through the inhibi-
tion of protein synthesis and partly through enhanced protein
degradation. To confirm these results in vivo, Cheng et al. gen-
erated a miR-196a transgenic mouse and bred it with transgenic
mice expressing mutant Htt fused to green fluorescent pro-
tein (GFP). The expression of miR-196a and mutant Htt were
up- and down-regulated, respectively, in the brain of double
transgenic mice, confirming the in vitro results. Moreover, inhi-
bition by miR-196a also occurred at later stages of the disease
in double transgenic mice when more Htt aggregates accumu-
lated. Because the double transgenic mouse model represents a
model of over-expression, Chen et al. evaluated the inhibition of
mutated Htt via miR-196a by transfecting induced pluripotent
stem cells derived from individuals with HD (HD-iPSCs) with
lentiviral vector encoding for miR-196a. As expected, untreated
cells accumulated more mutated Htt aggregates, whereas cells
transfected with miR-196a were characterized by lower expres-
sion of mutated Htt, suggesting that miR-196a can alleviate the
pathological phenotypes in human samples. The downstream
effect of miR-196a over-expression on Htt metabolism was inves-
tigated; the ubiquitin-proteosome system, gliosis, cAMP response
element-binding protein pathway, and several neuronal regula-
tory pathways were implicated (Cheng et al., 2013). All of these
evidences suggest a potential therapeutic role of miR-196a in HD.
miRNAs in the peripheral tissues of HD patients
Even though the ultimate trait biomarker is represented by
mutated Htt, many efforts have focused on identifying mRNAs
or proteins with expression profiles that could correlate with
disease progression. Gaughwin et al. developed a cell model of
HD (HTT-Exon-1 over-expressing human cell line) in order to
identify miRNA biomarkers. Briefly, they transfected an embry-
onal carcinoma-derived pluripotent cell line (NT2) capable of
differentiating into neurons with Htt-Exon-1 construct carry-
ing 23, 73, and 145 polyglutamine repeats. Microarray analysis
revealed two known miRNAs (miR-34b and miR-1285) that are
increased in the presence of 73Q-Htt and 145Q-Htt compared
to23Q-Htt. Based on these data, they investigated the expression
levels of miR-34b and miR-1285 in human plasma, demonstrat-
ing that they are detectable in human samples and bio-stable
relative to proteins. When the investigation was expanded to
plasma fromHD patients, miR-34b was increased in pre-manifest
HD plasma relative to age-matched controls (Gaughwin et al.,
2011). In contrast, no correlation was found for miR-1285. These
results suggest that miR-34b behaves as a potential biomarker of
HD prior to symptom onset. Despite the novelty of the results
obtained, a limitation of this study was the small patient cohort,
which needs to be enlarged.
THERAPEUTIC miRNAs FOR NDDs
The essential properties of a drug are favorable bioavailability,
a reasonable half-life, and few side effects. These requirements
are dependent on the type of drug, the target organ, and on
the delivery system used. An ideal vector for in vivo delivery
of RNA molecules should be equipped with a cationic group
for effective transfection, an endosomolytic group for endoso-
mal escape, a surface modifier to decrease steric hindrance, which
enhances circulation in the blood, and a targeting moiety to
direct the delivery system at target cells or tissue (Whitehead
et al., 2009). From the injection of miRNA agonists/antagonists
and knockdown of target genes/endogenous miRNAs, physiolog-
ical barriers represent the first obstacle to the efficacy of drug
treatment. Many checkpoints are represented by glomerular fil-
tration, hepatic metabolism, reticular endothelial system (RES)
uptake, and endothelial barriers. If injected as naked molecules,
RNA is subjected to nuclease degradation, which is responsible for
70% knockdown of drug efficacy within 1min of administration
(Mahato et al., 1995). To avoid the action of nucleases, chem-
ical modification or non-viral carriers can be used (Borchard,
2001;Wang et al., 2002; Crooke, 2004; Juliano, 2005; Juliano et al.,
2008). RNA particles>200 nm delivered to liposomes, lipoplexes,
polyplexes, or nanoparticles are subjected to phagocytosis by
RES (Alexis et al., 2008), and those smaller than 100 nm are the
target of hepatic Kupffer cells. Conjugation with non-viral car-
riers might induce marked toxicity because RNA molecules will
also enter the non-targeted cells due to an interaction between
the negatively charged cellular membrane and cationic carriers
(Uyechi et al., 2001). This effect might be reduced by coating
carriers with hydrophilic molecules (polyethylene glycol) or by
conjugation with a ligand (e.g., surface receptor-specific antibod-
ies) (Balyasnikova et al., 2002). Furthermore, RNA molecules can
be associated with aptamers, monoclonal antibodies, or peptides
to target specific cell surface receptors and the desired target in
the body (Juliano, 2005; Chu et al., 2006; Kumar et al., 2008).
After RNA molecules have passed these physiological barriers,
they have to enter the target cells to elicit their actions. This means
that they have to cross the cell membrane, escape endosomes, and
localize in the nucleus. Therefore, nuclear-localization signals and
cell-penetrating and endosomal-release signal peptides can influ-
ence the duration of action of injected RNAmolecules (Jere et al.,
2009).
In vivo delivery of RNA can be achieved two ways: systemat-
ically and locally (Figure 1). A great amount of drug is required
when it is injected systemically. In contrast, local delivery allows a
small amount of drug to be administered with reduced side effects
(Pardridge, 2007; Pushparaj et al., 2008; Shen, 2008). Notably, sys-
temic delivery is preferred when the target organ is the liver as the
majority of systemically administered drug molecules localize to
the liver. Efforts have been made to deliver RNA molecules across
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FIGURE 1 | Advantages and drawbacks of a miRNA-based therapy for the treatment of NDDs.
the BBB by in vivo systemic delivery, but it remains a major chal-
lenge in the treatment of NDDs. In particular, physical methods,
such as ultrasound (Chen et al., 2010; Liu et al., 2010), and the
intra-arterial infusion of compounds that disrupt the BBB (e.g.,
potassium channel agonists and minoxidil sulphate) increase the
chances of overcoming the BBB (Ningaraj et al., 2007; Bidros
et al., 2010). Recently, Alvarez-Erviti et al. experimented the deliv-
ery of RNA molecules associated with exosomes across the BBB.
Exosomes are cell-derived vesicles that enable cell-to-cell commu-
nication by transferring RNA molecules and proteins. They have
been shown to preserve mRNAs and miRNAs in the presence of
RNase and subsequently deliver them to recipient cells (Valadi
et al., 2007; Skog et al., 2008; Zomer et al., 2010). In particu-
lar, Alvarez-Erviti et al. isolated brain-targeting exosomes from
dendritic cells bioengineered to express an exosomal membrane
protein (Lamp 2b) fused to a ligand of the acetylcholine receptor.
Exosomes were then loaded with siRNAs targeting BACE1mRNA
by electroporation and injected intravenously, resulting in a sig-
nificant knock-down of BACE1 expression (Alvarez-Erviti et al.,
2011).
Efficient local delivery strategies for the CNS are intranasal,
intracerebroventricular, intrathechal, or intraparenchymal injec-
tion of naked RNAi formulated in isotonic saline buffer
(Makimura et al., 2002). Adenoviral, lentiviral, and adeno-
associated virus-based local delivery has also been performed
in animal models of AD, HD (Harper et al., 2005), and ALS
(Ralph et al., 2005), demonstrating significant improvement.
Nevertheless, the strategy to locally deliver a drug to the brain
is still far from normal practice because of the complexities
associated with direct injection into the brain.
CONCLUSION
Following the discovery of miRNAs, their actions were investi-
gated in almost all biological processes and, even more impor-
tantly, their central role in gene-expression regulation implicated
in many human diseases (Subramanian et al., 2008; Thum et al.,
2008; Eisenberg et al., 2009; Malumbres et al., 2009; Matkovich
et al., 2009; Crist and Buckingham, 2010; Maciotta et al., 2012).
miRNAs are of particular interest in understanding complex
disorders, such as NDDs, because they can potentially regulate
several pathways involved in the insurgence and progression of
the disease. In the last few years, miRNAs have also been con-
sidered as biomarkers; they offer several advantages over mRNA
or protein, including increased stability and biological relevance
in many different diseases. In fact, miRNAs offer the possi-
bility to link a biomarker with an altered biological process
and therapy capable of targeting the pathological mechanism.
miRNA-based therapeutic treatments for NDDs may follow two
different strategies: miRNA over-expression (gain-of-function)
or miRNA repression (loss-of-function) (Figure 1). The first
approach might use miRNA-associated target gene specificity in
order to down-regulate the expression of the aberrant gene within
the cell of interest; the second should use miRNAs to directly
influence the differentiation of neural stem cells (NSCs) (Palm
et al., 2012).
In the last few years, the hypothesis that miRNAs could be
involved in NDDs has gained support (Hebert and De Strooper,
2007) due to many experiments with different animal models,
such as the fly and mouse. Much experimental data demonstrate
that the miRNA network is necessary for neuron survival (Hebert
and De Strooper, 2009). Experiments conducted in humans sup-
port the idea that changes in miRNA expression profiles or
miRNA targets could increase the risk of major NDDs, such as
AD and PD (Tables 1, 2).
miRNA research seems particularly promising for understand-
ing not only the very prevalent and poorly understood sporadic
forms of AD, but also forms of PD. The challenge now is to
understand the role of specific miRNAs in biological models
and translate this knowledge to clinical studies (Hebert and De
Strooper, 2009).
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The use of miRNAs as potential therapeutic targets remains
controversial with regard to methods of delivery and target
specificity. When considering a treatment for NDDs medi-
ated by miRNA delivery, we have to evaluate its ability to
pass through the BBB. In order to overcome the problem of
the BBB, several siRNA delivery systems are being developed
for in vivo purposes, including vector-based, chemically mod-
ified, and “packaged” RNA oligonucleotides (Kim and Rossi,
2007). Progress in the latter area will immediately translate
into progress in the miRNA area because both are based on
the same principles. Both small RNAs regulate at the post-
transcriptional level; therefore, miRNAs and siRNAs are chem-
ically identical. However, the big question is whether these
different approaches will result in clinically feasible therapies
because of bioavailability and toxicity issues inherent to all of
these approaches, and the BBB constitutes an enormous hur-
dle for the effective delivery of these experimental drugs in the
brain.
Oligonucleotides can be effectively deployed in animal mod-
els, and RNA complexity provides the opportunity to uncover
novel regulatory mechanisms and biomarkers. A limit to clinical
miRNA use is that much remains to be improved in the predic-
tion of target genes for both miRNAs and lncRNAs (Johnson
et al., 2012).The most effective way of interfering with ncRNA
action is likely not by targeting the RNA/target gene interaction
itself, but to target the recruited epigenetic apparatus; this offers
the advantage of exploiting a growing array of chemical com-
pounds aimed at the active sites of chromatin modifiers (Kelly
et al., 2010). At the very least, this expanded view of the impor-
tance of RNA, both protein-coding and non-coding, both small
and large, offers an abundance of novel interactions to target
that are distinct from the current focus on protein regulation in
neurodegeneration.
Small ncRNAs add a novel and exciting layer of complex-
ity to molecular neuronal biology. In addition, publications will
exponentially increase in the years to come, which will pro-
vide novel insights into this recently discovered field of research
(Hebert and De Strooper, 2009). A “many to many” relation-
ship exists between miRNAs and their target mRNAs. The ability
of a single miRNA to potentially target as many as 200 dif-
ferent miRNAs is well documented, but there is also evidence
of single mRNA being targets of multiple miRNAs. To put this
complex “many to many” relationship in a biological context,
a comprehensive analysis of all miRNA targets suggested to be
regulated by a singlemiRNA generally constitutes a biological net-
work of functionally associated molecules in human cells. This
evidence may represent a limitation for the use of regulatory
small RNAs as a biomarker in NDDs or for future clinical tri-
als to treat NDDs. However, miRNAs might help extract some
biologically relevant targets among the high number of “pre-
dicted targets” of individual miRNAs, and potentially serves
as a filter when using pathway analysis tools to understand
the functional pathways affected by miRNA profile changes in
NDDs.
In conclusion, many scientific questions remain to be
addressed before efficient delivery and/or modulation of miRNAs
in the brain will be possible (Krutzfeldt et al., 2005, 2007).
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